The company will try to get the Komzifti QTc prolongation warning removed.
ApexOnco Front Page
Recent articles
It’s less about being fast, more about producing a better product.
As pivotal data approach, the French group pays $210m for ex-US rights.
Duality takes its Adam9-targeting conjugate into the clinic.
It’s a new term for biotech and its investors.
Pumitamig is the latest to be tested in first-line disease.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
